Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma

Batinac, Tanja; Hlača, Nika; Simetić, Luka; Valković, Frane; Peternel, Sandra; Prpić-Massari, Larisa

doi:10.2340/actadv.v102.1433

Pregled bibliografske jedinice broj: 1178949

Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma

Batinac, Tanja; Hlača, Nika; Simetić, Luka; Valković, Frane; Peternel, Sandra; Prpić-Massari, Larisa

Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma // Acta dermato-venereologica, 102 (2022), adv00650, 3 doi:10.2340/actadv.v102.1433 (međunarodna recenzija, članak, stručni)

CROSBI ID: 1178949 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma

Autori
Batinac, Tanja ; Hlača, Nika ; Simetić, Luka ; Valković, Frane ; Peternel, Sandra ; Prpić-Massari, Larisa

Izvornik
Acta dermato-venereologica (0001-5555) 102 (2022); Adv00650, 3

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
anemia ; cobimetinib ; melanoma ; Stevens-Johnson syndrome ; pembrolizumab ; vemurafenib

Sažetak
Targeted therapy with a BRAF inhibitor and a MEK inhibitor (BRAFi/MEKi) is a well-established treatment option for patients with BRAF-mutated advanced stage melanoma. In disease progression, sequencing between immune checkpoint inhibitors and BRAFi/ MEKi is a common approach. Recently, the question of efficacy, tolerability and possible toxicity of sequential therapy has been raised. We report here the first case of concomitant development of Stevens- Johnson syndrome and isolated severe anaemia in a patient undergoing treatment with vemurafenib plus cobimetinib following pembrolizumab therapy for advanced stage BRAF-mutated melanoma.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Projekti:
--uniri-pr-biomed-19-4 - Spitzoidni melanocitni tumori - kliničko-patološka, imunohistokemijska i genomska obilježja (Peternel, Sandra) ( CroRIS)

Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Zagreb,
Klinički bolnički centar Rijeka,
Sveučilište u Rijeci,
Fakultet zdravstvenih studija u Rijeci

Profili:

Tanja Batinac (autor)